Advanced search×

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.

Jaspreet J Pannu, Yoshihide Y Asano, Sashidhar S Nakerakanti, Edwin E Smith, Stefania S Jablonska, Maria M Blaszczyk, Peter P ten Dijke, and Maria M Trojanowska

Arthritis Rheum 58(8):2528-37 (2008) PMID 18668566

Activation of Smad1 signaling has recently been implicated in the development of fibrosis. The goal of the present study was to gain further insights into activation of the Smad1 pathway in fibrosis in systemic sclerosis (SSc) and to determine whether this pathway is targeted by the antifibrotic drug imatinib mesylate.

DOI: 10.1002/art.23698
Version: za2963e q8zae q8zbb q8zc0 q8zd6 q8zec q8zfb q8zg2

Similar articles you may find interesting…

  1. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...
    Mark Cascione, Daniel Wynn, and Kevin McCague

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....
  2. A randomized controlled trial of group cognitive behavioral therapy for Chinese breast cancer patients with major depression.
    Jianyin Qiu, Weijun Chen, and Min Yang

    J Psychosom Obstet Gynaecol (2013) PMID 23646866

    Patients in the GCBT group had a significant reduction in the 17-HAMD mean score by 9 points (p < 0.001) more reduction from baseline to six-month follow-up...
  3. Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4).
    Yuichi Tamura, Tomohiko Ono, and Shigetake Sasayama

    Adv Ther (2013) PMID 23653230

    Switching from epoprostenol GM to the same dose of epoprostenol AS was well tolerated over 12 weeks of treatment, and pulmonary hemodynamics were maintained. Switching to epoprostenol AS was also associated with improvements in treatment satisfaction (convenience). Clinical Trials: JapicCTI-122017....